Frequency of variants of hereditary cancer risk syndrome in 1682 Brazilian patients genotyped by next-generation sequencing

Short Title: Variants of hereditary cancer risk in 1682 Brazilian patients

Jarbas Maciel de Oliveira^{1,2*}, Nuria Bengala Zurro³, Antonio Victor Campos Coelho³, Marcel Pinheiro Caraciolo³, Rodrigo Bertollo de Alexandre³, George de Vasconcelos Carvalho Neto³, Ivana Grivicich² and João Bosco de Oliveira Filho^{3*}

- ¹ Hospital Memorial Arcoverde, Avenida José Bonifácio 1121, Arcoverde, Pernambuco 56503-740, Brazil
- ² Programa de Pós Graduação em Biologia Celular e Molecular Aplicada à Saúde, Universidade Luterana do Brasil, Av. Farroupilha 8001, Canoas Rio Grande do Sul 92425-020, Brazil
- ³ Hospital Israelita Albert Einstein, Avenida Albert Einstein 627, São Paulo 05652-900, Brazil
- * Corresponding author

<u>jarbasmaciel@yahoo.com.br</u> (JMO) or <u>joao.bosco@einstein.br</u> (JBOF)

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Abstract

1

23

2 Hereditary cancer risk syndromes are a group of disorders caused by germline 3 variants in a growing number of genes. Most studies on hereditary cancer have 4 been conducted in white populations. Here we report the largest study in 5 Brazilian individuals with multiple, self-reported, ethnicities. We genotyped 1682 6 individuals from all regions of the country who were referred to genetic testing 7 for hereditary cancer risk with multigene Next-generation sequencing (NGS) 8 panels. Most were women, and had a personal and/or family history of cancer. 9 The majority of cancer cases were breast and ovarian. We identified a total of 10 321 pathogenic/likely pathogenic (P/LP) variants in 305 people (18.1%), 11 corresponding to 166 unique variants. These variants were distributed among 12 32 genes, and most were detected on BRCA1 and BRCA2 (129 patients, 26.2% 13 and 14.3% of all P/LP hits, respectively). The prevalence of any genes 14 transheterozygosity in our sample was 0.89% (15/1682). The BRCA1/BRCA2 double heterozygosity rate was 0.78% (1/129) for BRCA variants carriers and 15 16 0.06% (1/1682) overall. We classified patients according to the NCCN and 17 Brazilian National Health Agency (ANS) genetic testing recommendation 18 criteria. We found that the criteria had false negative rates of 17.3% and 44.2%, 19 meaning that both failed to detect a substantial part of P/LP positive patients. 20 Therefore, our results show that NGS adds to knowledge on the Brazilian 21 spectrum of germline variants associated with cancer risk and indicate that 22 Brazilian testing guidelines should be improved.

genetics, colorectal cancer.

Introduction

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

Hereditary cancer risk syndromes are a group of disorders caused by germline pathogenic variants in a growing number of genes. They are the main predisposing factor in about 5-10% of all diagnosed cancers. Accurate genetic diagnosis in patients with hereditary cancer risk syndromes may reduce morbidity and mortality by allowing the adoption of specific preventative and therapeutic measures. Additionally, family members at risk can be tested and counseled, extending the clinical benefits to many individuals ¹. Currently, there are over 30 hereditary cancer syndromes already described, the most prevalent being hereditary breast and ovarian cancer syndrome (HBOC). Other syndromes include Li-Fraumeni, Cowden, Lynch, Familial Adenomatous Polyposis (APC), multiple Endocrine Neoplasia Type 1 or Wermer's Syndrome (MEN1), multiple Endocrine Neoplasia Syndrome - Type 2 (RET), and Von Hippel-Lindau Syndrome (VHL), to cite the most common. Most syndromes are inherited in an autosomal-dominant manner, with variable penetrance, and are caused by mutations in oncogenes or tumor suppressor genes 2. Although initially hard to diagnose genetically, the advent of nextgeneration sequencing (NGS) has allowed for testing using panels with dozens to hundreds of genes simultaneously and inexpensively ³. This has caused a great increase in the clinical use of these NGS panels, while a growing body of evidence show their clinical utility as compared to single-gene testing 4,5.

Although large studies have been published on the diagnostic utility of such panels, these are mostly restricted to white populations. The aim of this study was to describe the frequency and type of germline pathogenic variants in cancer susceptibility genes in patients with clinical criteria of hereditary cancer syndrome by NGS in the genetically admixed Brazilian population.

Materials and methods

Inclusion and exclusion criteria

The cohort to the retrospective study included 1682 Brazilian patients who received a multi-gene NGS panel for risk of hereditary cancer in the Genomika diagnostics unit, a genetics laboratory of the Albert Einstein Israeli Hospital (Genomika-Einstein hereafter). As this study took place in a private diagnostic laboratory this cohort was not specifically selected for any sex, age, ethnicity, or history of cancer. Both patients with or without criteria for hereditary risk cancer syndrome were considered. After genetic assessment we classified patients according to the USA National Comprehensive Cancer Network (NCCN, www.nccn.org) guidelines: genetic/familial high-risk assessment versions 3.2019 and 1.2020. Non-Brazilian patients were excluded.

Research ethics statement

This project was approved by the Institutional review board from the Research Ethics Committee of the Institute of Integral Medicine Professor Fernando Figueira (CEP-IMIP) in Recife, Pernambuco and all individuals

70 29567220.4.1001.0071).

69

71

72

82

83

Multigene genotyping panel

73 Genotyping was performed through panels that covered the entire coding 74 region including 20 bp flanking each exon and noncanonical splice region. 75 Patients were sequenced with panels that ranged from 27 to 78 genes, 76 including genes mostly associated with hereditary cancer risk, such as APC, 77 ATM, BARD1, BMPR1A, BRCA1, BRCA2, CDH1, CDK4, CHEK2, EGFR, 78 EPCAM, GREM1 HOXB13, MEN1, MITF, MLH1, MRE11A, MSH2, MSH6, 79 MUTYH, NBN, PALB2, PMS2, POLD1, POLE, PTEN, RAD50, RAD51C, RAD51D, RB1, RET, SMAD4, STK11, TP53, VHL. The complete list of genes is 80 81 available in the Table A.1).

Library preparation for NGS

84 Laboratory procedures were performed at Genomika-Einstein units 85 (Recife - PE and São Paulo - SP). Genomic DNA was extracted from peripheral 86 blood or saliva by automation (QIASymphony platform, QIAGEN, Hilden, 87 Germany) using the DNA Mini Kit extraction kit (QIAGEN). The quality and 88 quantity of the extracted DNA were assessed by fluorometry (Qubit, Thermo 89 Fisher, Waltham, Massachusetts). The genomic DNA was enzymatically 90 fragmented and enriched. The fragments were barcoded via multiplexed PCR 91 technology by QIAseq Targeted DNA Panels (CDHS 174272-2274 QIAGEN). 92 The genes were sequenced on MiSeg or Next-Seg 550 instruments (Illumina,

High-throughput kit (300 cycles) with 100% coverage and 50X minimum depth.

Sanger sequencing

In cases where variant confirmation was deemed necessary (low read depth, complex indels), the genotype was determined by conventional PCR followed by Sanger sequencing on an ABI 3500 (Thermo Fisher, Waltham, Massachusetts) automatic sequencer. The variant call was made via the reference transcript from the ATG initiation codon aligned against the GRCh37 / hg19 reference genome.

Alu insertion identification

Relevant genetic screenings of breast/ovarian cancer families of Portuguese ancestry demonstrate that the c.156_157ins*Alu* variant is the most frequent *BRCA2* rearrangement. Detection of this variant was performed as published elsewhere ⁶. Briefly, PCR of *BRCA2* exon 3 was performed and the *Alu* insertion is detected by differential agarose gel electrophoresis.

Variant classification and bioinformatic analysis

Bioinformatic analysis was performed using GATK 3.0 best practices. VCFs were annotated using Annovar and in-house databases. The clinical significance of the variants was determined according to the criteria of the American College of Genomics and Genetics (ACMG) 2015 guidelines for sequence variant interpretation and 2018 guideline update ^{7, 8}. Each variant

classification were performed independently by two specialists. Allelic frequency was examined through access to population databases as Genome

Aggregation Database (gnomAD) ⁹, Exome Aggregation Consortium (ExAC) ¹⁰, and The 1000 Genomes Project ¹¹. Disease information were upload form

ClinVar ¹² and the Leinden Open Variation Database (LOVD) ¹³. All variant information used for classification were updated and upgraded in an in-house local knowledgebase.

Results

117

118

119

120

121

122

123

124

125

Study sample characteristics and cancer histories

126 Between July 2016 and July 2019, we collected samples and 127 clinical/demographic characteristics from 1682 Brazilian individuals referred to a 128 private laboratory to undergo genotyping with a cancer hereditary risk 129 multigenic panel (Table 1). 130 Among the individuals, 1557 (92.6%) were women with mean age of 47.4 131 \pm 12.3 (range 11-88) years and 125 (7.4%) were men with mean age of 51.4 \pm 132 15.2 (range 14-91) years. Regarding ethnic ancestry, 1007 (59.9%) individuals 133 reported unknown background, 330 (19.6%) reported having multiple ethnicities 134 (admixed), 259 (15.4%) white, 26 (1.5%) black, 22 (1.3%) Ashkenazi Jewish, 21 135 (1.2%) native indigenous and 17 Asian (1.0%) (Table 1). 136 Personal cancer history was reported by 1126 (66.9%) individuals, with 137 breast or ovary cancers identified in 971 individuals (57.7%); colorectal cancer 138 in 71 (4.2%); thyroid/parathyroid in 36 (2.1%); prostate cancer in 15 (0.9%); 139 stomach cancer in 14 (0.8%); uterus, kidney, and sarcomas in 13 each (0.8%); 140 leukemia in 11 (0.6%); non-melanoma skin and pancreas cancers in 9 each

(0.5%); and melanoma in 6 (0.4%). Other types of cancer (lung, liver, bladder, larynx etc.) were identified in 17 individuals (1.0%). Overall, 268 individuals (15.9%) did not present malignant neoplasms and for 293 individuals (17.4%) the history information was not available.

Family cancer history (considering first-, second- or third-degree relatives) was reported by 1182 (70.3%) individuals: 806 (47.9%) reported breast cancer family history; 310 (23.0%) colorectal cancers; 339 (20.2%) prostate cancer; 219 (13.0%) head and neck tumors; 172 (10.2%) lung cancer; 155 (9.2%) stomach cancer; 119 (7.1%) breast and ovarian and 48 (2.9%) ovarian cancer exclusively. No family history was reported by 163 (9.7%) individuals and 337 (20.0%) did not provide information regarding family history (Table 1, Table A.2).

Genetic findings

Pathogenic or likely pathogenic variants were found in 305 (18.1%) of the 1682 individuals. Additionally, 1252 variants of uncertain significance (VUS) were found in 753 (44.8%) individuals (Fig. 1A, Table A.3). The remaining 624 (37.1%) patients did not present any variants of clinical interest whatsoever (negatives).

The 305 individuals collectively had 321 pathogenic/likely pathogenic variant hits (corresponding to 166 unique variants) in 32 genes: *APC, ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CHEK2, EPCAM, FANCC, MEN1, MITF, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, POLD1, PTCH2, PTEN, RAD50, RAD51, RAD51C, RAD51D, RB1, RECQL, RET and TP53.*

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

The genes that most commonly presented pathogenic or likely pathogenic variants were *BRCA1* (84/321 = 26.2%), *BRCA2* (46, 14.3%) and PALB2 (25, 7.8%). Lynch syndrome genes (MLH1, MSH2, MSH6 and PMS2) came next with 17 (5.3%) and were tied with TP53, also with 17 (5.3%) hits. Next came ATM (15, 4.7%), CHEK2 (14, 4.4%), RAD51C (9, 2.8%), RAD51 (8, 2.5%), RAD50 (7, 2.2%), BRIP1 (6, 1.9%), BARD1 (4, 1.2%), PTEN (4, 1.2%), RAD51D (4, 1.2%) and APC (3, 0,9%). Other genes amounted 17 (3.0%) variants (NBN, RET, biallelic MUTYH, MITF, CDH1, EPCAM, FANCC, MRE11, POLD1, RB1, RECQL, MEN1, CDK4 and PTCH2). Moreover, monoallelic MUTYH variants, considered to have low penetrance, were detected in 42 (13.1%) cases (Fig. 1B). In terms of unique variants, we detected 24 in BRCA1, 32 in BRCA2, 16 in PALB2, 16 in the Lynch syndrome genes, eight in TP53, 14 in ATM, eight in CHEK2, six in RAD51C, nine in RAD51, two in RAD50, six in BRIP1, four in PTEN, two in RAD51, three in APC, two in NBN, eight in MUTYH, two in CDH1 and one each in BARD1, RET, MITF, EPCAM, FANCC, MRE11, POLD1, RB1. RECQL, MEN1, CDK4 and PTCH2. Among the 321 pathogenic/likely pathogenic variant hits, 84 (26.2%) were point mutations in conserved splice sites, 73 (22.7%) were frameshift deletions, 65 (20.2%) were missense point mutations, 58 (18.1%) were nonsense point mutations, 22 (6.9%) were frameshift duplications, 10 (3.1%) were frameshift insertions, four (1.3%) were frameshift indels, four inframe deletions (1.3%), and a single inframe insertion (0.3%) (Fig. 1C). Most of the 1252 VUS hits (corresponding to 886 unique variants) were identified in ATM (198 hits, 15.8%), followed by BRCA2 (86, 6.9%), MHS6 (63,

5.0%), BRIP1 (55, 4.4%), RAD50 (52, 4.2%), CHEK2 (38, 3.0%), PALB2 (34,

2.7%), MHS2 (31, 2.5%), MLH1 (17, 1.4%), TP53 (17, 1.4%), BRCA1 (17,

1.4%). Other genes amounted to 644 (51.4%) VUS (Fig. 1D).

Individuals with multiple variants (transheterozygotes)

Among the 305 individuals with pathogenic/likely pathogenic variants, 290 (95.1%) were single heterozygotes, 14 (4.6%) presented two variants in different genes (any two of these: *APC, ATM, BRCA1, BRCA2, CDK4, CHEK2, MEN1, MUTYH, PALB2, PMS2, RAD51, RAD51C* or *TP53*) and a single patient (0.3%) presented three pathogenic variants in different genes (*BRCA1, MSH6* and *MUTYH*). The most common combination in the patients with two variants was a variant in a high-penetrance gene, such as *BRCA1* and *BRCA2*, alongside a variant with lower penetrance, such as monoallelic *MUTYH* or in *CHEK2*. No patients presented more than one pathogenic/likely pathogenic variants in the same gene (Fig. 2, Table A.4). We observed a single individual *BRCA1/BRCA2* double heterozygote, making the double heterozygotes prevalence among *BRCA* variants carriers about 0.78% (1/129) and 0.06% (1/1682) overall. Thus, the overall transheterozygosity prevalence was about 0.89% (15/1682) in our sample.

Positivity profiles according to testing criteria of the USA National Comprehensive Cancer Network and Brazilian National

Health Agency

The sampled individuals were assessed for hereditary cancer testing indication according to two sets of clinical criteria: the NCCN for hereditary

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

breast/ovarian, colorectal, stomach or pancreas cancer syndromes, version 3.2019 and 1.2020 and the criteria of the Brazilian National Health Agency (ANS). Among the 1682 individuals in study, 1008 (59.9%) met NCCN 3.2019 and 1.2020 criteria for testing, 368 (21.9%) did not meet the criteria and 306 did not have sufficient information for classification. Forty-five patients among the 305 that presented pathogenic/likely pathogenic (positive patients) were in the last group, leaving 260 classifiable patients. The true positive rate of NCCN criteria was 215/260 (82.7%) and the false negative rate was 45/260 (17.3%). The F1-measure was 33.9%. Regarding ANS criteria, 660 (39.2%) met the criteria for testing, 691 did not meet and 331 did not have sufficient information for classification. The true positive rate of ANS was 145/260 (55.7%) and the false negative rate was 115/260 (44.2%), and F1-measure was 31.5% (Table 2). The group of 215 patients fulfilling testing criteria according to the NCCN had the following genetic profiles: 72 (36.4%) individuals having variants in BRCA1, 29 (14.6%) in BRCA2, 16 (8.1%) in PALB2, 14 (7.1%) in TP53, 11 (5.6%) in ATM, 9 (4.5%) in CHEK2, 7 (3.5%) in RAD50 and RAD51, 6 (3.5%) in RAD51C, 4 (2.0%) in MSH6, 3 (1.5%) in BRIP1, MSH2 and RAD51D, 2 (1.0%) in APC, BARD1 and CDH1 e 8 (4.0%) in other genes (MEN1, MITF, MLH1, NBN, PMS2, POLD1, PTEN and RECQL). The group of 45 patients who did not meet the NCCN criteria had the following profiles: 9 (20.0%) individuals with variants in MUTYH, 7 (16.7%) in BRCA2, 6 (14.3%) in BRCA1, 5 (11.9%) in PALB2, 2 (4.8%) in ATM, CHEK2,

MLH1, MSH6, PTEN, RET and TP53, besides 10 (23.8%) in other genes

(BARD1, BRIP1, CDK4, FANCC, MRE11A, MSH2, PMS2, PTCH2, RAD51 and RAD51C).

In summary, both NCCN 1.2020/3.2019 and ANS criteria failed to detect a substantial part of positive patients. The Brazilian criteria fared even worse, missing about 44% of positive patients, versus approximately 17% with NCCN 1.2020/3.2019.

Geographic distribution of variants

We stratified our data according to each Brazilian state. The results are available in the Table A.5.

Discussion

Cancers were the second most common cause of death worldwide in 2018, with 9.6 million deaths (1 every 6 deaths). Lung, prostate, colorectal, stomach and liver are the most common in men, whereas women are more affected by breast, colorectal, lung, cervix and thyroid ¹⁴. The Brazilian National Cancer Institute (INCA) estimates 450,000 new cancer cases per year (excluding non-melanoma skin cancers) for the 2020-2022 triennium ¹⁵.

Most tumors are sporadic, caused by somatic genetic events. However, about 10% of the patients carry germline pathogenic variants in cancer predisposition genes such as *BRCA1* or *BRCA2* ¹. The identification of these patients is of utmost clinical importance because early diagnosis of hereditary cancer risk syndromes may improve vigilance and treatment. Therefore, genetic

investigation is already a tool of modern oncology ¹⁶.

Next generation sequencing (NGS) technologies reduced sequencing costs allowing rapid, precise, and simultaneous analysis of a great quantity of genetic material. NGS has been used to identify genetic causes of rare diseases and cancers, in clinical and research settings. Previously, patients in investigation of HBOC or Lynch syndrome risk would be genotyped by limited, specific panels. Nowadays, as NGS is being largely utilized by clinical laboratories, the patients may undergo genotyping by multigenic panels that allow a better stratification as well as personalized oncologic management ¹⁷.

Here, we report the results of our study, the largest conducted in Brazil, with 1682 individuals that underwent genotyping with 27- to 78-genes panels intended to detect germinative variants in cancer predisposition genes. Women are the majority in our sample (92.6%). Consequently, the most prevalent cancers were breast and ovarian (57.7%), colorectal (4.2%) and thyroid/parathyroid (2.1%).

The overall positivity rate was 18.1% (305/1682 individuals); 16.0% (269/1682) if individuals with monoallelic *MUTYH* variants are excluded. Considering just *BRCA1/BRCA2* pathogenic/likely pathogenic variants, the positivity rate was only 7.7% (129/1682 individuals). This demonstrates the importance of NGS multigene panels: it reduces the rate of false negatives, providing more information for oncologic management and prognosis.

The *BRCA* pathogenic variants positivity rate from our study seems low, but it is not unexpected since our cohort was not specifically selected for any sex, age, ethnicity, or history of cancer. Indeed, since there is significant allelic heterogeneity in *BRCA* genes, there is great variability in positivity rates in other studies ¹⁸. In Brazil, studies of HBOC patients observed positivity rates between

1.3% ¹⁹ and 27.3% ²⁰. In other countries, the positivity rate among sporadic and high-risk hereditary cancer cases varied between 2.6% in the USA ²¹ and 27.9% in Japan ²² (reviewed in ²³). Therefore, our positivity rate is indeed within these ranges.

We compared the mutational profile of *BRCA1* and *BRCA2* genes we observed with other 20 Brazilian studies. Among the 56 variants we detected, 33 (19 in *BRCA1* and 14 in *BRCA2*) were recurrent in other studies. The five most recurrent variants were: *BRCA1*:c.5266dupC, found by other 18 studies ^{18, 20, 24-39}, *BRCA1*:c.3331_3334delCAAG, found in other 12 studies ^{18, 20, 24, 27, 29, 31, 32, 34, 35, 37, 39, 40}, *BRCA2*:c.2808_2811delACAA found in other seven studies ^{18, 29-31, 34, 35, 39}, *BRCA1*: c.1687C>T found in six studies ^{26, 31, 32, 34, 35} and *BRCA1*:c.211A>G found in other five studies ^{35-38, 40}.

The five most prevalent *BRCA1* mutations among the individuals sampled by our study were c.5266dupC, c.5074+2T>C, c.3331_3334delCAAG, c.1687C>T and c.211A>G. These results partially agree with a worldwide survey that included Brazilian families of women carriers of *BRCA* pathogenic variants. Rebbeck et al. (2018) ⁴¹ surveyed 101 Brazilian families and observed c.5266dupC, c.3331_3334delCAAG and c.1687C>T among the five most prevalent *BRCA1* mutations. Therefore, our results agree with three variants.

The five most prevalent *BRCA2* variants in our patients were c.2808_2811delACAA, c.9382C>T, c.6024dupG, c.8488-1G>A and c.5216dupA. Only c.2808_2811delACAA was in common with the Rebbeck et al. results ⁴¹. Interestingly, they observed c.156_157insAlu among the five most prevalent variation among 49 Brazilian families, but our results place it in sixth place, tied with other variants.

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

The recurrence in independent samples from Brazil indicate the variants are representative of the BRCA1 and BRCA2 mutational spectrum in Brazil. Indeed, the BRCA1:c.5266dupC and BRCA2:c.156_157insAlu (found in other four studies ^{31, 34, 35, 42}) variants are considered as founder mutations coming from European populations and may be found in the individuals from all regions of Brazil 35. Indeed, we detected BRCA1: c.5266dupC in individuals from Pernambuco and Alagoas, Northeast Brazil states, as well as in São Paulo (Southeast) and Paraná (South) and BRCA2:c.156 157insAlu was detected in an individual from Piauí, also a Northeast state. We also observed some recurrent pathogenic variants in other genes: TP53:c.1010G>A, found in four other studies ^{20, 38-40}, CHEK2:c.349A>G, found in two other studies ^{38, 43}; MUTYH:c.1147delC ⁴³; MUTYH:c.1187G>A ³⁸, MSH2:c.2152C>T 44; MSH6:c.3848 3862del 45, MLH1:c.677G>A 44 and PALB2:c.2257C>T 46. These observations could mean that these variants are important co-players alongside the recurrent BRCA variants in the risk of hereditary cancers in Brazilian populations. Transheterozygosity, i.e. heterozygosity at two different loci ⁴⁷, is rare among patients at risk of hereditary cancers. The prevalence of double heterozygosity among BRCA1/BRCA2 carriers ranges between 1.8% and 1.85% 48, 49 in the Jewish Ashkenazi populations. Among non-Ashkenazi Europeans, the prevalence is lower, between 0.22% and 0.87% ⁴⁸. An Italian study reported 0.62% 50 and a Korean study reported 1.2% 51. Therefore, our estimate of 0.78% in the Brazilian sample seems plausible. There has been controversy regarding the consequences over the phenotype of BRCA1/BRCA2 double heterozygote. Earlier reports suggest that

they do not have worse phenotypes when comparing to single-variant carriers ^{52, 53}. Bell et al. (2002) ⁵⁴ analyzed three independent samples of tumor tissue from the same *BRCA1/BRCA2* double heterozygote patient and observed that either one or other gene had suffered loss of heterozygosity (LOH) genetic events, suggesting that both genes are functionally equivalent in initiating tumorigenesis in breast tissue. Therefore, double heterozygote status would be equivalent to single-carrier status. Other case reports, case series and review of case reports also suggested that double heterozygote status was not associated with more severe phenotype ^{48, 55, 56}. In contrast, Randall et al. (1998) ⁵⁷ observed LOH in both genes in ovarian tumors, perhaps signaling that the pathogenic events in each tissue are different and not always *BRCA1* mutations are equivalent to *BRCA2* counterparts.

However, more recent large surveys have been suggesting that double heterozygote have different phenotypes when compared to single heterozygote individuals. A large survey of 8162 German families with breast/ovarian cancer cases found eight double heterozygote individuals. They observed that they were younger at the onset of their first cancer episode when compared with their single heterozygote relatives and had more severe disease ⁵⁸. A worldwide survey of 32,295 women compared the clinical history of double heterozygote individuals with breast cancer to their single heterozygote counterparts. The same was done for ovarian cancer cases. They observed that clinical characteristics of double heterozygote individuals resemble phenotypes from *BRCA1*-only single heterozygotes, but tumor LOH microsatellite markers patterns are intermediate to the patterns of *BRCA1*-only single heterozygote and *BRCA2*-only single heterozygote. Thus, the authors suggest that the joint

effect of *BRCA1/BRCA2* variants are compatible with an additive model ⁴⁷. Another recent study also suggests that the double heterozygote phenotype more closely resembled that of *BRCA1* mutation carriers with poor prognosis factors and proposed a co-dominant model for the joint effects ⁵⁹.

In summary, *BRCA1/BRCA2* double heterozygote may have early onset of disease and the phenotype is perhaps similar to the "severe end of spectrum of *BRCA1* mutation carriership" ⁴⁸. We found a single *BRCA1/BRCA2* double heterozygote woman in our sample. She presented personal history of breast cancer. Since she is in her late 40s, her first cancer case must have happened much earlier, however, detailed data on her phenotype is currently lacking.

Literature on *BRCA*/other genes double heterozygotes is sparser. Thus, comparison with our results was difficult due to the possible different combinations of variants. For example, Sokolenko et al. (2014) ⁶⁰ found seven digenic combinations double heterozygotes among *BRCA1* and other DNA double-strand repair genes (*BRCA1/CHEK2*, *BRCA1/ATM*, *BRCA1/BLM*, *CHEK2/BLM*, *CHEK2/ATM*, *NBS1/ATM*, and *NBS1/BLM*) in Russian patients: none were observed in our study. They did not observe differences from single heterozygote individuals. In contrast, a case series including a German *BRCA1/PALB2* double heterozygous patient had no early onset but had severe disease (multifocal triple negative ductal carcinoma) ⁶¹. Another case report presented a case of a double heterozygote *APC/MLH1* man with Kashmir/Egyptian ancestry, which had a history of six jejunal cancers ⁶². Therefore, double heterozygosity may have unusual effects on cancer phenotypes. However, we did not find *APC/MLH1* double heterozygous, but

found an individual *APC/TP53* double heterozygote, so it is another case warranting further investigation.

Perhaps the joint effects of non-*BRCA* variants can be explained in an additive manner as well. Thus, some combinations will result in severe phenotypes while others will not, due to the specific penetrance of each variant. It seems that non-*BRCA* double heterozygotes will need to be analyzed on a case-by-case basis.

We found that NCCN 1.2020 criteria missed a substantial proportion of patients that had pathogenic/likely pathogenic variants. Other authors observed the same. We found that NCCN criteria missed a substantial proportion of patients that had pathogenic/likely pathogenic variants. Other authors observed the same. For example, Grindedal et al. (2017) ⁶³ investigated *BRCA* mutations in a Norwegian breast cancer cohort and assessed some testing criteria, including NCCN, and found a false negative rate of 15.8%. Yang et al. (2018) ⁶⁴ investigated 4196 patients genotyped with 40- to 80- genes panels and showed a false negative rate of 13.5% with NCCN criteria. Both were not much far from our estimate of 17% with NCCN 1.2020/3.2019.

Other authors proposed changes to NCCN criteria. Alemar et al. (2017)

34 found that adding criteria that are not included in the NCCN and ANS criteria

(e.g. some ASCO criteria 65, 66) achieved a higher predictive value, while other

authors compared other four algorithms (BOADICEA 67, 68, BRCAPRO, Myriad

69 and Manchester score 70) and observed that the pedigree-based BOADICEA

most accurately predicted *BRCA1/BRCA2* variant carrier status in a

Southeastern Brazilian population 71. Although NCCN criteria were imperfect,

ANS criteria fared worse and a reformulation is warranted.

Recently, a panel of Brazilian experts proposed recommendations for improving testing criteria for HBOC risk patients in Brazil. Besides modifying testing criteria, the expert panel also recommended offering risk-reducing surgeries for positive patients. For negative patients, investigating both maternal and paternal lineages is warranted, so the result of models estimating cancer risk can be communicated to the patient. They also suggested that VUS should always be reported and periodically reassessed, but no urgent clinical action is justified since most VUS are constantly reclassified to benign/likely benign categories. Furthermore, patients should be contacted whenever any update in testing protocols or management options should appear ⁷².

Our study had some limitations. The NGS panel detects small deletions and duplications up to 17 base-pairs, but large deletions and duplications are not detected by this methodology. Other structural chromosomal changes, such as inversions and translocations are not detected either. If some of these changes are suspected, we recommend using methodologies like array CGH, MLPA, qPCR or FISH to confirm the variant found. Expansion variants of trinucleotide repeats, deep intronic variants or regulatory regions such as promoters are not detectable in the present test. Epigenetic changes are also not detectable by this test. At least for *BRCA* genes though, large rearrangements seem to be uncommon in Brazilian populations ^{35, 42}. Moreover, further phenotype information was missing for several patients, precluding further analyses.

Conclusion

434

435

436

437

438

439

440

441

442

443

444

445

446

455

In conclusion, we genotyped 1682 Brazilian individuals with clinical criteria of hereditary cancer syndrome from all regions of the country with NGS multigenic panels suited for the detection of germline pathogenic variants associated with cancer susceptibility, making it the largest Brazilian study of this nature to date. We observed several *BRCA1* and *BRCA2* recurrent mutations, confirming their presence in the Brazilian mutational spectrum and generated data for other 30 genes and 110 variants with modest penetrance. We also estimated the prevalence of *BRCA* as well as non-*BRCA* double heterozygotes in the Brazilian population. More studies are necessary to discover the implication of transheterozygosity over the phenotype of affected individuals.

Appendix

- 447 **Table A.1.** Genotyped genes.
- **Table A.2.** Ancestry, genetic findings summary, testing criteria, personal and
- 449 family history.
- 450 **Table A.3.** Genetic Findings.
- **Table A.4.** Positivity rate per gene or combination of genes, alongside number
- 452 of unique pathogenic/likely pathogenic variants detected in each gene. The
- 453 variants are detailed for transheterozygotes.
- 454 **Table A.5.** Patients per Brazilian state.

References

- 456 1. Samadder NJ, Giridhar KV, Baffy N, Riegert-Johnson D, Couch FJ.
- 457 Hereditary Cancer Syndromes-A Primer on Diagnosis and Management: Part 1:
- 458 Breast-Ovarian Cancer Syndromes. Mayo Clin Proc. Jun 2019;94(6):1084-1098.
- 459 doi:10.1016/j.mayocp.2019.02.017
- 460 2. Nagy R, Sweet K, Eng C. Highly penetrant hereditary cancer syndromes.
- 461 Oncogene. 2004;23(38):6445-6470. doi:10.1038/sj.onc.1207714

- 462 3. Zelli V, Compagnoni C, Cannita K, et al. Applications of Next Generation
- 463 Sequencing to the Analysis of Familial Breast/Ovarian Cancer. High Throughput.
- 464 Jan 10 2020;9(1)doi:10.3390/ht9010001
- 465 4. Xuan J, Yu Y, Qing T, Guo L, Shi L. Next-generation sequencing in the
- 466 clinic: Promises and challenges. Cancer Letters. 2013;340(2):284-295.
- 467 doi:10.1016/j.canlet.2012.11.025
- 468 5. Yohe S, Thyagarajan B. Review of Clinical Next-Generation Sequencing.
- 469 Archives of Pathology & Laboratory Medicine. 2017;141(11):1544-1557.
- 470 doi:10.5858/arpa.2016-0501-ra
- 471 6. Machado PM, Brandao RD, Cavaco BM, et al. Screening for a BRCA2
- 472 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder
- 473 effect and analysis of the associated phenotypes. J Clin Oncol. May 20
- 474 2007;25(15):2027-34. doi:10.1200/JCO.2006.06.9443
- 475 7. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the
- 476 interpretation of sequence variants: a joint consensus recommendation of the
- 477 American College of Medical Genetics and Genomics and the Association for
- 478 Molecular Pathology. Genet Med. May 2015;17(5):405-24.
- 479 doi:10.1038/gim.2015.30
- 480 8. Biesecker LG, Harrison SM, ClinGen Sequence Variant Interpretation
- 481 Working G. The ACMG/AMP reputable source criteria for the interpretation of
- 482 sequence variants. *Genet Med.* Dec 2018;20(12):1687-1688.
- 483 doi:10.1038/gim.2018.42
- 484 9. Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint
- 485 spectrum quantified from variation in 141,456 humans. Nature. 2020/05/01
- 486 2020;581(7809):434-443. doi:10.1038/s41586-020-2308-7
- 487 10. Karczewski KJ, Weisburd B, Thomas B, et al. The ExAC browser:
- 488 displaying reference data information from over 60 000 exomes. Nucleic Acids
- 489 Research. 2017;45(D1):D840-D845. doi:10.1093/nar/gkw971
- 490 11. A global reference for human genetic variation. Nature.
- 491 2015;526(7571):68-74. doi:10.1038/nature15393
- 492 12. Landrum MJ, Lee JM, Benson M, et al. ClinVar: improving access to
- 493 variant interpretations and supporting evidence. Nucleic Acids Research.
- 494 2018;46(D1):D1062-D1067. doi:10.1093/nar/gkx1153
- 495 13. Fokkema IFAC, Taschner PEM, Schaafsma GCP, Celli J, Laros JFJ, Den
- 496 Dunnen JT. LOVD v.2.0: the next generation in gene variant databases. *Human*
- 497 *Mutation*. 2011;32(5):557-563. doi:10.1002/humu.21438
- 498 14. Organization WH. WHO report on cancer: setting priorities, investing
- 499 wisely and providing care for all. 2020.
- 500 15. Instituto Nacional de Câncer José Alencar Gomes da Silva. Ministério da
- 501 Saúde. Estimativa 2020: incidência de câncer no Brasil. Rio de Janeiro: Instituto
- Nacional de Câncer José Alencar Gomes da Silva; 2019. p. 120.
- 503 16. Yoshida R. Hereditary breast and ovarian cancer (HBOC): review of its
- molecular characteristics, screening, treatment, and prognosis. Breast Cancer.
- 505 Aug 29 2020;doi:10.1007/s12282-020-01148-2
- 506 17. Suwinski P, Ong C, Ling MHT, Poh YM, Khan AM, Ong HS. Advancing
- 507 Personalized Medicine Through the Application of Whole Exome Sequencing and
- 508 Big Data Analytics. Front Genet. 2019;10:49. doi:10.3389/fgene.2019.00049
- 509 18. Alemar B, Herzog J, Brinckmann Oliveira Netto C, et al. Prevalence of
- 510 Hispanic BRCA1 and BRCA2 mutations among hereditary breast and ovarian
- 511 cancer patients from Brazil reveals differences among Latin American

- 512 populations. *Cancer Genet*. Sep 2016;209(9):417-422.
- 513 doi:10.1016/j.cancergen.2016.06.008
- 514 19. Dillenburg CV, Bandeira IC, Tubino TV, et al. Prevalence of 185delAG and
- 515 5382insC mutations in BRCA1, and 6174delT in BRCA2 in women of Ashkenazi
- 516 Jewish origin in southern Brazil. Genet Mol Biol. Jul 2012;35(3):599-602.
- 517 doi:10.1590/S1415-47572012000400009
- 518 20. Cipriano NM, Jr., de Brito AM, de Oliveira ES, et al. Mutation screening of
- 519 TP53, CHEK2 and BRCA genes in patients at high risk for hereditary breast and
- 520 ovarian cancer (HBOC) in Brazil. Breast Cancer. May 2019;26(3):397-405.
- 521 doi:10.1007/s12282-018-00938-z
- 522 21. Susswein LR, Marshall ML, Nusbaum R, et al. Pathogenic and likely
- 523 pathogenic variant prevalence among the first 10,000 patients referred for next-
- 524 generation cancer panel testing. Genet Med. Aug 2016;18(8):823-32.
- 525 doi:10.1038/gim.2015.166
- 526 22. Sugano K, Nakamura S, Ando J, et al. Cross-sectional analysis of germline
- 527 BRCA1 and BRCA2 mutations in Japanese patients suspected to have hereditary
- 528 breast/ovarian cancer. *Cancer Sci.* Oct 2008;99(10):1967-76.
- 529 doi:10.1111/j.1349-7006.2008.00944.x
- 530 23. Okano M, Nomizu T, Tachibana K, et al. The relationship between BRCA-
- 531 associated breast cancer and age factors: an analysis of the Japanese HBOC
- 532 consortium database. *J Hum Genet*. Mar 2021;66(3):307-314.
- 533 doi:10.1038/s10038-020-00849-y
- 534 24. Lourenço JJ, Vargas FR, Bines J, et al. BRCA1 mutations in Brazilian
- patients. Genetics and Molecular Biology. 2004;27:500-504.
- 536 25. Dufloth RM, Carvalho S, Heinrich JK, et al. Analysis of BRCA1 and BRCA2
- 537 mutations in Brazilian breast cancer patients with positive family history. Sao
- 538 Paulo Med J. Jul 7 2005;123(4):192-7. doi:10.1590/s1516-31802005000400007
- 539 26. Gomes MC, Costa MM, Borojevic R, et al. Prevalence of BRCA1 and
- 540 BRCA2 mutations in breast cancer patients from Brazil. *Breast Cancer Res Treat*.
- 541 Jul 2007;103(3):349-53. doi:10.1007/s10549-006-9378-6
- 542 27. Esteves VF, Thuler LC, Amendola LC, et al. Prevalence of BRCA1 and
- 543 BRCA2 gene mutations in families with medium and high risk of breast and
- 544 ovarian cancer in Brazil. Braz J Med Biol Res. May 2009;42(5):453-7.
- 545 doi:10.1590/s0100-879x2009000500009
- 546 28. Ewald IP, Izetti P, Vargas FR, et al. Prevalence of the BRCA1 founder
- 547 mutation c.5266dupin Brazilian individuals at-risk for the hereditary breast and
- 548 ovarian cancer syndrome. Hered Cancer Clin Pract. Dec 20 2011;9(1):12.
- 549 doi:10.1186/1897-4287-9-12
- 550 29. Carraro DM, Koike Folgueira MA, Garcia Lisboa BC, et al. Comprehensive
- 551 analysis of BRCA1, BRCA2 and TP53 germline mutation and tumor
- characterization: a portrait of early-onset breast cancer in Brazil. *PLoS One*.
- 553 2013;8(3):e57581. doi:10.1371/journal.pone.0057581
- 554 30. Silva FC, Lisboa BC, Figueiredo MC, et al. Hereditary breast and ovarian
- 555 cancer: assessment of point mutations and copy number variations in Brazilian
- 556 patients. *BMC Med Genet*. May 15 2014;15:55. doi:10.1186/1471-2350-15-55
- 557 31. Fernandes GC, Michelli RA, Galvão HC, et al. Prevalence of
- 558 BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary
- 559 breast cancer and characterization of its genetic ancestry. Oncotarget. Dec 6
- 560 2016;7(49):80465-80481. doi:10.18632/oncotarget.12610

- 561 32. Maistro S, Teixeira N, Encinas G, et al. Germline mutations in BRCA1 and
- 562 BRCA2 in epithelial ovarian cancer patients in Brazil. BMC cancer. Dec 3
- 563 2016;16(1):934. doi:10.1186/s12885-016-2966-x
- 564 33. de Oliveira ES, Soares BL, Lemos S, et al. Screening of the BRCA1 gene
- in Brazilian patients with breast and/or ovarian cancer via high-resolution melting
- 566 reaction analysis. Article. Fam Cancer. Apr 2016;15(2):173-181.
- 567 doi:10.1007/s10689-015-9858-0
- 568 34. Alemar B, Gregório C, Herzog J, et al. BRCA1 and BRCA2 mutational
- profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands
- 570 from Southern Brazil: Are international testing criteria appropriate for this specific
- 571 population? *PLOS ONE*. 2017;12(11):e0187630.
- 572 doi:10.1371/journal.pone.0187630
- 573 35. Palmero EI, Carraro DM, Alemar B, et al. The germline mutational
- 574 landscape of BRCA1 and BRCA2 in Brazil. Sci Rep. Jun 15 2018;8(1):9188.
- 575 doi:10.1038/s41598-018-27315-2
- 576 36. Brianese RC, Nakamura KDM, Almeida F, et al. BRCA1 deficiency is a
- 577 recurrent event in early-onset triple-negative breast cancer: a comprehensive
- 578 analysis of germline mutations and somatic promoter methylation. Breast Cancer
- 579 Res Treat. Feb 2018;167(3):803-814. doi:10.1007/s10549-017-4552-6
- 580 37. Cotrim DP, Ribeiro ARG, Paixão D, et al. Prevalence of BRCA1 and
- 581 BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian
- 582 carcinoma patients in Brazil. BMC cancer. Jan 3 2019;19(1):4.
- 583 doi:10.1186/s12885-018-5235-3
- 584 38. Bandeira G, Rocha K, Lazar M, et al. Germline variants of Brazilian women
- 585 with breast cancer and detection of a novel pathogenic ATM deletion in early-
- 586 onset breast cancer. *Breast Cancer*. Sep 28 2020;doi:10.1007/s12282-020-587 01165-1
- 588 39. Da Costa E Silva Carvalho S, Cury NM, Brotto DB, et al. Germline variants
- in DNA repair genes associated with hereditary breast and ovarian cancer
- 590 syndrome: analysis of a 21 gene panel in the Brazilian population. *BMC Medical*
- 591 Genomics. 2020;13(1)doi:10.1186/s12920-019-0652-y
- 592 40. Felix GE, Abe-Sandes C, Machado-Lopes TM, et al. Germline mutations
- 593 in BRCA1, BRCA2, CHEK2 and TP53 in patients at high-risk for HBOC:
- 594 characterizing a Northeast Brazilian Population. Hum Genome Var.
- 595 2014;1:14012. doi:10.1038/hgv.2014.12
- 596 41. Rebbeck TR, Friebel TM, Friedman E, et al. Mutational spectrum in a
- 597 worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. *Hum Mutat*.
- 598 May 2018;39(5):593-620. doi:10.1002/humu.23406
- 599 42. Ewald IP, Cossio SL, Palmero EI, et al. BRCA1 and BRCA2
- 600 rearrangements in Brazilian individuals with Hereditary Breast and Ovarian
- 601 Cancer Syndrome. *Genet Mol Biol*. Apr-Jun 2016;39(2):223-31.
- 602 doi:10.1590/1678-4685-gmb-2014-0350
- 603 43. Felicio PS, Grasel RS, Campacci N, et al. Whole-exome sequencing of
- 604 non-BRCA1/BRCA2 mutation carrier cases at high-risk for hereditary
- 605 breast/ovarian cancer. *Hum Mutat.* Dec 16 2020;doi:10.1002/humu.24158
- 606 44. Soares BL, Brant AC, Gomes R, et al. Screening for germline mutations in
- 607 mismatch repair genes in patients with Lynch syndrome by next generation
- 608 sequencing. Fam Cancer. Jul 2018;17(3):387-394. doi:10.1007/s10689-017-
- 609 0043-5

- 610 45. Rosa RCA, Santis JO, Teixeira LA, et al. Lynch syndrome identification in
- a Brazilian cohort of endometrial cancer screened by a universal approach.
- 612 Gynecol Oncol. Oct 2020;159(1):229-238. doi:10.1016/j.ygyno.2020.07.013
- 613 46. Gomes R, Spinola PDS, Brant AC, et al. Prevalence of germline variants
- in consensus moderate-to-high-risk predisposition genes to hereditary breast and
- ovarian cancer in BRCA1/2-negative Brazilian patients. *Breast Cancer Res Treat.*
- 616 Oct 30 2020;doi:10.1007/s10549-020-05985-9
- 617 47. Rebbeck TR, Friebel TM, Mitra N, et al. Inheritance of deleterious
- 618 mutations at both BRCA1 and BRCA2 in an international sample of 32,295
- 619 women. Breast Cancer Research. Nov 11 2016;18112. doi:10.1186/s13058-016-
- 620 0768-3
- 48. Leegte B, van der Hout AH, Deffenbaugh AM, et al. Phenotypic expression
- of double heterozygosity for BRCA1 and BRCA2 germline mutations. J Med
- 623 Genet. Mar 2005;42(3):e20. doi:10.1136/jmg.2004.027243
- 49. Lavie O, Narod S, Lejbkowicz F, et al. Double heterozygosity in the BRCA1
- and BRCA2 genes in the Jewish population. *Ann Oncol.* Apr 2011;22(4):964-966.
- 626 doi:10.1093/annonc/mdq460
- 627 50. Zuradelli M, Peissel B, Manoukian S, et al. Four new cases of double
- heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and
- 629 family characteristics. Breast Cancer Res Treat. Nov 2010;124(1):251-8.
- 630 doi:10.1007/s10549-010-0853-8
- 631 51. Noh JM, Choi DH, Nam SJ, et al. Characteristics of double heterozygosity
- 632 for BRCA1 and BRCA2 germline mutations in Korean breast cancer patients.
- 633 Breast Cancer Res Treat. Jan 2012;131(1):217-22. doi:10.1007/s10549-011-
- 634 1718-5
- 635 52. Friedman E, Bar-Sade Bruchim R, Kruglikova A, et al. Double
- 636 heterozygotes for the Ashkenazi founder mutations in BRCA1 and BRCA2 genes.
- 637 Am J Hum Genet. Oct 1998:63(4):1224-7. doi:10.1086/302040
- 638 53. Moslehi R, Russo D, Phelan C, Jack E, Antman K, Narod S. An unaffected
- 639 individual from a breast/ovarian cancer family with germline mutations in both
- 640 BRCA1 and BRCA2. Clin Genet. Jan 2000;57(1):70-3. doi:10.1034/j.1399-
- 641 0004.2000.570111.x
- 642 54. Bell DW, Erban J, Sgroi DC, Haber DA. Selective loss of heterozygosity in
- multiple breast cancers from a carrier of mutations in both BRCA1 and BRCA2.
- 644 Cancer Res. May 15 2002;62(10):2741-3.
- 645 55. Thiffault I, Hamel N, Pal T, et al. Germline truncating mutations in both
- 646 MSH2 and BRCA2 in a single kindred. *Br J Cancer*. Jan 26 2004;90(2):483-91.
- 647 doi:10.1038/sj.bjc.6601424
- 648 56. Musolino A, Naldi N, Michiara M, et al. A breast cancer patient from Italy
- 649 with germline mutations in both the BRCA1 and BRCA2 genes. Breast Cancer
- 650 Res Treat. May 2005;91(2):203-5. doi:10.1007/s10549-004-7704-4
- 651 57. Randall TC, Bell KA, Rebane BA, Rubin SC, Boyd J. Germline mutations
- of the BRCA1 and BRCA2 genes in a breast and ovarian cancer patient. *Gynecol*
- 653 *Oncol.* Sep 1998;70(3):432-4. doi:10.1006/gyno.1998.5081
- 654 58. Heidemann S, Fischer C, Engel C, et al. Double heterozygosity for
- 655 mutations in BRCA1 and BRCA2 in German breast cancer patients: implications
- 656 on test strategies and clinical management. Breast Cancer Research and
- 657 Treatment. Aug 2012;134(3):1229-1239. doi:10.1007/s10549-012-2050-4
- 658 59. Le Page C, Rahimi K, Rodrigues M, et al. Clinicopathological features of
- women with epithelial ovarian cancer and double heterozygosity for BRCA1 and

- 660 BRCA2: A systematic review and case report analysis. *Gynecol Oncol.* Feb 2020;156(2):377-386. doi:10.1016/j.ygyno.2019.11.019
- 662 60. Sokolenko AP, Bogdanova N, Kluzniak W, et al. Double heterozygotes
- among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations. *Breast Cancer Res Treat.* Jun 2014;145(2):553-
- 665 62. doi:10.1007/s10549-014-2971-1
- 666 61. Pern F, Bogdanova N, Schürmann P, et al. Mutation analysis of BRCA1,
- 667 BRCA2, PALB2 and BRD7 in a hospital-based series of German patients with
- 668 triple-negative breast cancer. PLoS One. 2012;7(10):e47993.
- 669 doi:10.1371/journal.pone.0047993
- 670 62. Lindor NM, Smyrk TC, Buehler S, et al. Multiple jejunal cancers resulting
- 671 from combination of germline APC and MLH1 mutations. Fam Cancer. Dec
- 672 2012;11(4):667-9. doi:10.1007/s10689-012-9561-3
- 673 63. Grindedal EM, Heramb C, Karsrud I, et al. Current guidelines for BRCA
- 674 testing of breast cancer patients are insufficient to detect all mutation carriers.
- 675 BMC cancer. 2017;17(1):438-438. doi:10.1186/s12885-017-3422-2
- 676 64. Yang S, Axilbund JE, O'Leary E, et al. Underdiagnosis of Hereditary
- 677 Breast and Ovarian Cancer in Medicare Patients: Genetic Testing Criteria Miss
- 678 the Mark. Ann Surg Oncol. Oct 2018;25(10):2925-2931. doi:10.1245/s10434-
- 679 018-6621-4

- 680 65. Statement of the American Society of Clinical Oncology: genetic testing
- 681 for cancer susceptibility, Adopted on February 20, 1996. J Clin Oncol. May
- 682 1996;14(5):1730-6; discussion 1737-40. doi:10.1200/JCO.1996.14.5.1730
- 683 66. Lu KH, Wood ME, Daniels M, et al. American Society of Clinical Oncology
- 684 Expert Statement: collection and use of a cancer family history for oncology
- 685 providers. *J Clin Oncol*. Mar 10 2014;32(8):833-40.
- 686 doi:10.1200/JCO.2013.50.9257
- 687 67. Antoniou AC, Pharoah PD, McMullan G, et al. A comprehensive model for
- 688 familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J
- 689 Cancer. Jan 7 2002;86(1):76-83. doi:10.1038/sj.bjc.6600008
- 690 68. Antoniou AC, Pharoah PP, Smith P, Easton DF. The BOADICEA model of
- 691 genetic susceptibility to breast and ovarian cancer. Br J Cancer. Oct 18
- 692 2004;91(8):1580-90. doi:10.1038/sj.bjc.6602175
- 693 69. Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for
- 694 breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet. Jan
- 695 1998;62(1):145-58. doi:10.1086/301670
- 696 70. Evans DG, Eccles DM, Rahman N, et al. A new scoring system for the
- 697 chances of identifying a BRCA1/2 mutation outperforms existing models including
- 698 BRCAPRO. *J Med Genet*. Jun 2004;41(6):474-80. doi:10.1136/jmg.2003.017996
- 699 71. Teixeira N, Maistro S, Del Pilar Estevez Diz M, et al. Predictability of
- 700 BRCA1/2 mutation status in patients with ovarian cancer: How to select women
- 701 for genetic testing in middle-income countries. *Maturitas*. Nov 2017;105:113-118.
- 702 doi:10.1016/j.maturitas.2017.06.002
- 703 72. Achatz MI, Caleffi M, Guindalini R, Marques RM, Nogueira-Rodrigues A,
- 704 Ashton-Prolla P. Recommendations for Advancing the Diagnosis and
- 705 Management of Hereditary Breast and Ovarian Cancer in Brazil. JCO Glob Oncol.
- 706 2020;6:439-452. doi:10.1200/JGO.19.00170

Table 1. Demographic and clinical characteristics of Brazilian individuals tested genotyped with NGS hereditary cancer panel.

Demographic	N	%
Sex	1682	100
Female	1557	92.6
Male	125	7.4
Age at diagnosis (years)		
<30	79	4.7
30-40	452	26.9
41-50	526	31.3
51-65	465	27.6
>65	160	9.5
Ethnicity		
Multiple ethnicities (admixed)	330	19.6
White	259	15.4
Black	26	1.5
Jewish Ashkenazi	22	1.3
Native indigenous	21	1.2
Asian	17	1.0
No information	1007	59.9
Personal cancer history ^a		
Overall	1126	66.9
Breast or ovarian	971	57.7
Colorectal	71	4.2
Thyroid/parathyroid	36	2.1
Prostate	15	0.9
Stomach	14	0.8
Uterus	13	0.8
Kidney	13	0.8
Sarcomas	13	0.8
Leukemia	11	0.6
Skin (non-melanoma)	9	0.5
Pancreas	9	0.5
Other	17	1.0
No cancer history	268	15.9
No information	293	17.4

Family cancer history (first-, second- or third-degree relatives,	Family cancer history	(first-, second-	or third-degree	relatives)
---	-----------------------	------------------	-----------------	------------

Overall	1182	70.3
Breast or ovarian	973	57.8
Colorectal	310	18.4
Thyroid/parathyroid	108	6.4
Prostate	339	20.2
Stomach	155	9.2
Uterus	122	7.3
Kidney	45	2.7
Sarcomas	22	1.3
Leukemia	139	8.3
Skin (non-melanoma)	72	4.3
Pancreas	83	4.9
Other	235	14.0
No cancer history	163	9.7
No information	337	20.0

^a Number of individuals with personal history exceeds 1682 because some individuals reported multiple cancer types.

Table 2. NCCN 3.2019/1.2020 and Brazilian ANS testing criteria performance.

	NOO 4 4		
	NGS testing		_ Row
Decision	Positive patients	VUS/Negative	totals
		patients	เบเสเร
NCCN 3.2019/1.2020			
At risk	215	793	1008
No risk	45	323	368
Column totals	260	1116	1376
Insufficient information:			
306			
Brazilian ANS			
At risk	145	515	660
No risk	115	576	691
Column totals	260	1091	1351
Insufficient information:			
331			

NCCN: sensitivity = 82.7%, specificity = 28.9%, false negative rate = 17.3%, F1-measure = 33.9%.

ANS: sensitivity = 55.8%, specificity = 52.8%, false negative rate = 44.2% F1-measure = 31.5%.

Figure captions

Figure 1. Variants profiles. (A) Distribution of patients according to genetic findings. P/LP = patients with pathogenic/likely pathogenic, VUS = patients with variants of uncertain significance (N = 1682). (B) Distribution of P/LP variants per gene. (C) P/LP variants functional annotation. (D) Distribution of VUS per gene. Lynch syndrome genes have been grouped together in (C) and (D).

Figure 2. Heatmap representing the distribution of pathogenic/likely pathogenic (P/LP) transheterozygotes in the sample. The top line represents the number of patients in each column. The single heterozygotes (n=290) are distributed in the main diagonal. Transheterozygotes (n=15) are distributed in the inferior half (14 double-heterozygotes and 1 triple-heterozygote). The total number of variants are $321 (290 \times 1 + 14 \times 2 + 1 \times 3 = 321)$.



